molecules of the month

Compound 14f

oral ChemR23 inhibitor

Preclinical, immunology

from HTS, scaffold hopping and opt.

Bioorg. Med. Chem.

Kyowa Kirin

oral ChemR23 inhibitor - Kyowa Kirin
2 mins read

Context. Compound 14f (Kyowa Kirin) is an oral ChemR23 inhibitor with two acidic sites. Nominated by Bryan McKibben, this article describes a scaffold hopping exercise to address the short half-life of previously described chemical matter, and the successful development of in-vivo tool inhibitors to probe ChemR23 biology in animal models of inflammatory disease. An earlier ChemR23 inhibitor from Kyowa was previously highlighted in Jul. 2020. This article also describes the design of a fluorescein-labeled probe for the target. Target. ChemR23 (CMKLR1) is a chemokine-like, GPCR receptor implicated in dendritic, macrophage and NK-cell related inflammatory diseases including systemic lupus erythematosus (SLE), psoriasis and atherosclerosis. The ChemR23 inhibitor was developed with the intention of suppressing the migration of plasmacytoid dendritic cells (pDCs),…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: